Low diversity of the gut microbiota in infants with atopic eczema - 03/02/12
Abstract |
Background |
It is debated whether a low total diversity of the gut microbiota in early childhood is more important than an altered prevalence of particular bacterial species for the increasing incidence of allergic disease. The advent of powerful, cultivation-free molecular methods makes it possible to characterize the total microbiome down to the genus level in large cohorts.
Objective |
We sought to assess microbial diversity and characterize the dominant bacteria in stool during the first year of life in relation to atopic eczema development.
Methods |
Microbial diversity and composition were analyzed with barcoded 16S rDNA 454-pyrosequencing in stool samples at 1 week, 1 month, and 12 months of age in 20 infants with IgE-associated eczema and 20 infants without any allergic manifestation until 2 years of age (ClinicalTrials.gov ID NCT01285830).
Results |
Infants with IgE-associated eczema had a lower diversity of the total microbiota at 1 month (P = .004) and a lower diversity of the bacterial phylum Bacteroidetes and the genus Bacteroides at 1 month (P = .02 and P = .01) and the phylum Proteobacteria at 12 months of age (P = .02). The microbiota was less uniform at 1 month than at 12 months of age, with a high interindividual variability. At 12 months, when the microbiota had stabilized, Proteobacteria, comprising gram-negative organisms, were more abundant in infants without allergic manifestation (Empirical Analysis of Digital Gene Expression in R [edgeR] test: P = .008, q = 0.02).
Conclusion |
Low intestinal microbial diversity during the first month of life was associated with subsequent atopic eczema.
Le texte complet de cet article est disponible en PDF.Key words : Allergic disease, Bacteroides species, diversity, eczema, hygiene hypothesis, infant, microbiota, molecular microbiology, pyrosequencing, Sutterella species
Abbreviations used : edgeR, OTU, RDP
Plan
Supported by grants from BioGaia AB, Stockholm, Sweden; the Ekhaga Foundation, the Heart and Lung foundation; the Research Council for the South-East Sweden (grant no. F2000-106); the Olle Engqvist Foundation; the Swedish Asthma and Allergy Association; the Swedish Research Council; the University Hospital of Linköping; the Söderberg Foundation; and the Vårdal Foundation for Health Care Science and Allergy Research, Sweden. |
|
Disclosure of potential conflict of interest: B. Björkstén has received research support from BioGaia AB. M. C. Jenmalm has received lecture honoraria from BioGaia AB. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 129 - N° 2
P. 434 - février 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?